Torrent Pharma Q4FY26: Revenue Up 42%, Stock Hits High

Share price jumps, then pares gains

Torrent Pharmaceuticals shares rose sharply in early trade after its March quarter earnings and a round of brokerage updates. On the BSE, the stock gained 4.7% intraday to ₹4,698.8 per share. By 10:33 AM, it had pared some gains but was still up 4.03% at ₹4,665 per share. On the NSE, the stock touched a fresh 52-week high of ₹4,681 per share, up 4.34%.

The move came even as the company reported a year-on-year decline in quarterly profit. Market participants appeared to focus on the underlying operating performance, domestic growth, and commentary around the integration of JB Chemicals and Pharmaceuticals (JBCP). Brokerages described the operating outcome as broadly in line with estimates, while keeping varied stances on the stock’s risk-reward.

Q4FY26 profit falls on acquisition-related costs

Torrent reported consolidated profit after tax (PAT) of ₹364 crore for the quarter ended March 31, 2026. This compared with ₹498 crore in the corresponding quarter of the previous fiscal. The company attributed the decline to exceptional expenses, including regulatory fees and integration costs related to the JBCP acquisition.

The quarter was also described by brokerages as the first quarter of JBCP consolidation. As the integration progresses, near-term profitability can be influenced by one-off costs and operational changes such as harmonising systems, distribution structures, and sales processes.

Revenue rises 42% as India business leads growth

Despite the hit to PAT, revenue momentum remained strong. Torrent’s revenue from operations rose 42% year-on-year to ₹4,197 crore in Q4FY26 from ₹2,959 crore in Q4FY25.

The company linked the growth to domestic performance. India revenues increased 43% to ₹2,215 crore, with management commentary and brokerage notes pointing to outperformance in focus therapies and the performance of generic semaglutide.

Semaglutide and base portfolio performance in India

Brokerages highlighted that Torrent’s India base business grew 15% during the quarter, versus Indian pharmaceutical market (IPM) growth of 10% as per the Pharma Track data set referenced in reports.

Morgan Stanley noted that the semaglutide launch gained 38% share in the generic market. Nomura also referred to management expectations of mid-teens growth in India, supported by strong traction in semaglutide sales.

JBCP integration: near-term disruption, synergy targets reiterated

JBCP’s performance in Q4FY26 was described as being adversely impacted by integration with Torrent and changes in trade and sales-closing practices. Nomura flagged that distribution network optimisation and product basket rationalisation weighed on sales.

Management reiterated cost synergy guidance of ₹400-450 crore by the third year of consolidation. Nomura expects JBCP’s financial performance to improve in the coming quarters, as integration steps settle and synergy initiatives flow through.

Morgan Stanley added that the JBCP merger is nearing final approval from the National Company Law Tribunal (NCLT), while cost synergies of ₹400-450 crore remain on track over the next three years.

Brokerage views: targets cluster, but ratings differ

Analyst opinions remained mixed, reflecting the balance between strong domestic execution and integration complexity.

Nomura maintained a Neutral rating with a target of ₹4,670, and cited limited upside from current levels while tracking integration progress. Morgan Stanley kept an Equal Weight rating with a target price of ₹4,580, noting that excluding JBCP, revenue and EBITDA rose 16% year-on-year, led by India and semaglutide.

Jefferies reiterated a Buy rating with a target price of ₹5,350. It calculated an upside of 19.25% from the Friday close of ₹4,486.20 on the NSE, and said the March quarter included two months of JBCP integration with results broadly in line on a like-to-like basis.

Key numbers at a glance

Deal context: how Torrent structured the JBCP acquisition

Torrent’s acquisition of JBCP was outlined as a two-phase transaction at a fully diluted equity valuation of ₹25,689 crore. Torrent agreed to acquire a 46.39% stake via a share purchase agreement at ₹1,600 per share, amounting to ₹11,917 crore. The company also launched an open offer to buy up to 26% from public shareholders at ₹1,639.18 per share, and stated it intends to acquire 2.8% from certain employees at the same price offered to KKR.

As part of the proposed merger, JBCP shareholders would receive 51 Torrent shares for every 100 JBCP shares held, through a court-approved scheme. The transaction remains subject to shareholder approvals and Competition Commission of India (CCI) approval, with timelines referenced as around six months in brokerage and media reports.

Market impact and what investors are tracking

The immediate market reaction showed investors were willing to look past the quarter’s exceptional costs, focusing on revenue growth and domestic execution. Still, the divergence in brokerage ratings suggests investors are watching integration milestones closely, particularly how quickly JBCP stabilises after distribution and sales-practice changes.

Key near-term variables highlighted in notes include the pace of synergy capture, clarity on funding mix for the cash consideration, and regulatory progress on approvals. Management’s reiterated synergy target of ₹400-450 crore by year three remains a central benchmark for tracking integration outcomes.

Conclusion

Torrent Pharma’s stock touched fresh highs after Q4FY26 results, supported by 42% revenue growth and a strong India performance, even as PAT fell 27% due to JBCP-related exceptional costs. The next set of updates is likely to be read through the lens of integration progress, regulatory approvals, and the company’s ability to deliver on the ₹400-450 crore synergy roadmap.